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Abstract
Objective—Regular HIV RNA testing for all HIV positive patients on antiretroviral therapy 
(ART) is expensive and has low yield since most tests are undetectable. Selective testing of those 
at higher risk of failure may improve efficiency. We investigated whether a novel analysis of 
adherence data could correctly classify virological failure and potentially inform a selective testing 
strategy.
Design—Multisite prospective cohort consortium.
Methods—We evaluated longitudinal data on 1478 adult patients treated with ART and 
monitored using the Medication Event Monitoring System (MEMS) in 16 United States cohorts 
contributing to the MACH14 consortium. Since the relationship between adherence and 
virological failure is complex and heterogeneous, we applied a machine-learning algorithm (Super 
Learner) to build a model for classifying failure and evaluated its performance using cross-
validation.
Results—Application of the Super Learner algorithm to MEMS data, combined with data on 
CD4+ T cell counts and ART regimen, significantly improved classification of virological failure 
over a single MEMS adherence measure. Area under the ROC curve, evaluated on data not used in 
model fitting, was 0.78 (95% CI: 0.75, 0.80) and 0.79 (95% CI: 0.76, 0.81) for failure defined as 
single HIV RNA level >1000 copies/ml or >400 copies/ml, respectively. Our results suggest 25–
31% of viral load tests could be avoided while maintaining sensitivity for failure detection at or 
above 95%, for a cost savings of $16–$29 per person-month.
Conclusions—Our findings provide initial proof-of-concept for the potential use of electronic 
medication adherence data to reduce costs through behavior-driven HIV RNA testing.
Keywords
HIV; Adherence; Antiretroviral Therapy; Virological failure; HIV RNA monitoring; Medication 
Event Monitoring System; Super Learner
Introduction
Testing HIV patients’ plasma HIV RNA level every three months is the standard of care in 
resource-rich settings and is used to alert providers to the potential need for enhanced 
adherence interventions and/or the need to change a failing antiretroviral therapy (ART) 
regimen before accumulation of resistance mutations, disease progression, and death.1–3 
Routine serial HIV RNA testing for all patients on ART, however, is expensive and the 
majority of tests in patients on stable regimens yield undetectable HIV RNA.4–6
If sufficiently sensitive, a selective testing approach in which plasma HIV RNA is measured 
only when screening criteria suggest increased risk of virological failure might be used to 
reduce expense related to HIV RNA testing. However, several screening rules proposed to 
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date, based on either clinical data alone or some combination of clinical data and self-
reported adherence data, had low sensitivity (20–67%), particularly in validation 
populations.4–6 Pharmacy refill data were reported to classify failure with greater accuracy 
than self-reported adherence data,7 suggesting that alternate approaches to measuring 
adherence may improve a selective HIV RNA testing strategy.
Previous studies examining associations between adherence and virological failure have 
generally focused on a single summary of adherence data, such as average adherence over 
some interval preceding HIV RNA assessment.7–12 However, adherence patterns are myriad 
and the association of any one pattern with virological failure is unclear.8 Further, 
measurement of adherence, whether based on self-report, pill count, or electronic medication 
container opening, is inherently imperfect. Finally, electronic adherence monitoring 
methods, some of which transmit data in real time, are becoming more widely available. In 
summary, it is unknown how best to combine adherence and clinical data to predict 
virological failure.12,14–17 To address these challenges, we built prediction models for 
virological failure using Medication Event Monitoring System (MEMS) and clinical data 
analyzed with Super Learner, a data-adaptive algorithm based on cross-validation (i.e., 
multiple internal data splits).18,19
We investigated the potential for pill container openings recorded using MEMS to correctly 
classify virological failure in a large clinically and geographically heterogeneous population 
of HIV patients treated with ART in the United States. We investigated 1) the extent to 
which a machine learning method (Super Learner) applied to MEMS adherence and clinical 
data improved classification of failure beyond a single time-updated MEMS adherence 
summary; 2) the extent to which addition of MEMS to basic clinical data improved 
classification of failure; and, 3) the potential for the resulting risk score to reduce frequency 
of HIV RNA measurements while detecting at least 95% virological failures.
Methods
Patient population and outcome
We studied HIV positive patients in the Multisite Adherence Collaboration on HIV-14 
(MACH14) who underwent ART adherence monitoring with MEMS between 1997 and 
2009. MEMS monitoring consists of a date and time stamp recorded electronically with each 
pill container opening, subsequently downloaded to a database via USB. Details on the 
MACH14 population have been reported elsewhere.20 In brief, 16 studies based in 12 US 
states contributed longitudinal clinical, MEMS, and HIV RNA data to the consortium. 
Subjects were eligible for inclusion in our analyses if they had at least two plasma HIV 
RNA measurements during follow-up, with at least one of the postbaseline measurements 
preceded by MEMS monitoring in the previous month.
We considered two virological failure outcomes, defined as a single HIV RNA level >400 
copies/ml and >1000 copies/ml, respectively, the latter to improve specificity for true failure 
versus transient elevations (i.e., “blips”21) and facilitate comparison with previous 
studies.5,7,22 Baseline (first available) HIV RNA level was used as a predictor variable in 
some models, as detailed below. Post-baseline HIV RNA levels were included as outcome 
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variables if they were preceded by MEMS monitoring in the previous month. Follow-up was 
censored at first detected virological failure after baseline. Subjects could contribute 
multiple postbaseline HIV RNA tests as outcomes.
Candidate Predictor Variables
The first prediction model (“Clinical”) was built using the following non-virological 
candidate variables: time since study enrollment, baseline, nadir, and most recent CD4 
count, time since most recent CD4 count, ART regimen class (non-nucleoside reverse 
transcriptase inhibitor, boosted protease inhibitor, non-boosted protease inhibitor, and 
“other” regimens; Table 1), an indicator of change in regimen class in preceding two 
months, and time since any regimen change. Study site was excluded because, were the 
algorithm used in practice, site-specific fits would not generally be available. Additional 
potential predictor variables, including time since diagnosis and full treatment history, were 
missing on a large proportion of subjects (Table 1) and were not included as candidate 
predictors in this analysis.
The second prediction model (“Electronic Adherence/Clinical”) augmented the set of 
candidate predictors used in the non-virological clinical model with summaries of past 
MEMS data. MEMS data were used to calculate adherence summaries accounting for daily 
prescribed dosing over a set of intervals ranging from 1 week to 6 months preceding each 
outcome HIV RNA test. Dates of reported device non-use (due, for example, to 
hospitalization or imprisonment) were excluded from adherence calculations.
Adherence summaries included percent doses taken (# of recorded doses/# of prescribed 
doses), number of interruptions (consecutive days with no recorded doses) of 1,2, 3, and 4 
days duration, variance across days of percent doses taken per day, and versions of these 
summaries using only weekday and (for all but interruptions of >2 days) only weekend 
measurements. MEMS summaries for intervals over which no MEMS measurements were 
made were carried forward as their last observed value, and indicators of carry forward were 
included in the predictor set. This approach, unlike multiple imputation, reflects the data that 
would be available to inform a testing decision for a given patient. Number of drugs 
monitored, drug and drug class monitored, and number of days monitored with MEMS 
during each interval were also included.
Comparison of “Clinical” and “Electronic Adherence/Clinical” model performance 
evaluated the added value of MEMS data. We also investigated further gains from adding a 
single baseline HIV RNA measurement (“Baseline HIV RNA/Electronic Adherence/
Clinical”) and, because extent of past virological suppression can reflect adherence behavior 
and impact likelihood of resistance, full HIV RNA history (“HIV RNA/Electronic 
Adherence/Clinical”) to the set of candidate predictor variables. The latter included most 
recent HIV RNA value, time since most recent HIV RNA test, number of previous tests, and 
an indicator of regimen switch since last test.
Construction of Prediction Models
The Super Learner algorithm was applied to each set of candidate variables in turn to build 
four prediction models for each failure definition (HIV RNA level > 400 copies/ml and > 
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1000 copies/ml). Super Learner is described in detail elsewhere.18,19 In brief, we specified a 
library of candidate prediction algorithms that included Lasso regression,24 preliminary 
Lasso screening combined with a generalized additive model,25,26 a generalized boosted 
model,27 multivariate adaptive polynomial spline regression,28 and main term logistic 
regression. For comparison, percent of prescribed doses taken over the past 3 months was 
evaluated as a single time-updated predictor. To achieve a more balanced dataset and reduce 
computation time, all HIV RNA levels above failure threshold and an equal number of 
randomly sampled HIV RNA levels below threshold were used to build the models, with 
weights used to correct for sampling. The ability of this approach to build predictors with 
comparable or improved performance on the full sample is supported by theory and prior 
analyses,29 and was verified for this dataset using selected prediction models. Ten-fold 
cross-validation was used to choose the convex combination of algorithms in the library that 
achieved the best performance on data not used in model fitting, with the negative log 
likelihood used as loss function (i.e. performance metric).30.
Evaluation of Prediction Models
The performance of the Super Learner prediction model was evaluated using a second level 
of cross-validation, ensuring that performance was evaluated with data not used to build the 
model. The data were split into ten folds (partitions) of roughly equal size, with all repeated 
measures from a given individual contained in a single fold. The Super Learner algorithm 
was run on each training set (containing nine of the ten folds) and the performance of the 
selected model was evaluated with the corresponding validation set, which consisted 
exclusively of subjects not used to build the prediction model. Cross-validated performance 
measures averaged performance across validation sets.
Area under the Receiver Operating Characteristic Curve (AUROC) was used to summarize 
classification performance across the range of possible cutoffs for classifying a given test 
based on predicted failure probability. Standard error estimates, accounting for repeated 
measures on an individual, were calculated based on the influence curve.31 For each of a 
range of cutoffs, we also calculated sensitivity, specificity, negative and positive predictive 
value, and the proportion of HIV RNA tests for which the predicted probability of failure 
was below the cutoff. We refer to the latter metric as “capacity savings” because it reflects, 
for a given cutoff, the proportion of HIV RNA tests that would have been avoided under a 
hypothetical selective testing strategy in which HIV RNA tests were ordered only when a 
subject’s predicted probability of failure on a given day on which an HIV RNA test was 
scheduled was greater than the cutoff.
We estimated capacity savings corresponding to a range of sensitivities. For example, for 
each validation set we selected the largest cutoff for which sensitivity was >=95%, 
calculated the proportion of HIV RNA tests that had a predicted probability less than this 
cutoff, and averaged these proportions across validation sets. This provided an estimate of 
the proportion of HIV RNA tests that could have been avoided under a hypothetical 
selective testing rule chosen to detect at least 95% of failures without additional delay.
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Costing
We conducted a basic analysis to provide a rough estimate of the cost per month at which an 
electronic adherence monitoring system would remain cost neutral. For each candidate 
prediction model, we first estimated gross cost savings that would be achieved with cutoff 
chosen to maintain sensitivity >=95% as the number of post-baseline HIV RNA tests below 
cutoff times the estimated combined cost of an outpatient visit and HIV RNA test. We used 
an estimated unit cost for an outpatient primary care visit based on the 2014 Medicare 
National Physician Fee Schedule ($90–$140 for CPT-4 code 99214) and unit cost for an 
HIV RNA test of $50–$90. We divided gross cost savings by total person time under MEMS 
follow-up. Person time was calculated from beginning of MEMS monitoring to the 
minimum of last post-baseline HIV RNA test date and end of MEMS monitoring.
Analyses were performed using MatLab and R.32,33, including the ROCR, SuperLearner, 
and cvAUC R packages.34–36
Results
Sample Characteristics
Of the 2835 patients in the MACH14 cohort, 1478 patients met inclusion criteria and 
contributed a total of 3096 post-baseline HIV RNA tests to prediction of failure defined 
using a threshold of 1000 copies/ml. Consecutive postbaseline HIV RNA tests were a 
median of 45 days apart (IQR:28, 99; Table 1). Baseline and final HIV RNA tests were a 
median of 163 days (IQR 82, 282) apart. When failure was defined as >400 copies/ml, 2751 
post-baseline HIV RNA tests met inclusion criteria; baseline and final HIV RNA tests were 
a median of 143 days (IQR 66, 273) apart.
At baseline subjects had known of their HIV status for a median of 9.2 years (IQR 4.0, 
16.1), and the majority (83%) had past exposure to ART (Table 1). A median of 78 days of 
MEMS data (IQR 28, 91) were available in the three months preceding HIV RNA tests 
conducted after the baseline assessment. Over the 3 months preceding each postbaseline 
HIV RNA test, median percent doses taken, as measured by MEMS, was 84% (IQR 50, 98) 
and subjects had experienced a median of four interruptions >=24 hours in MEMS events 
(IQR 1,11). Using a threshold of 1000 and 400 copies/ml, respectively, 20% and 27% of 
post-baseline HIV RNA tests were failures and 41% and 51% of patients failed.
Classification of Failure
The Super Learner Algorithm applied to each of the three predictor sets that included 
MEMS data resulted in a higher cross-validated AUROC than MEMS-based measurement 
of three-month percent doses taken (Figure 1 and Table 2; p<0.001 for each pairwise 
comparison). The AUROC for classification of failure by three-month percent doses taken 
was 0.64 (95% CI 0.61, 0.67), and 0.60 (95% CI 0.57, 0.63) for HIV RNA failure thresholds 
of 1000 and 400 copies/ml, respectively.
With failure defined as >1000 copies/ml, the Super Learner model based on non-virological 
clinical predictors achieved moderate classification performance (“Clinical” AUROC: 0.71, 
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95% CI: 0.69, 0.74). Addition of MEMS data significantly improved performance 
(“Electronic Adherence/Clinical” AUROC: 0.78, 95% CI: 0.75, 0.80, p<0.001). Addition of 
a single baseline HIV RNA level (“Baseline HIV RNA/Electronic Adherence/Clinical” 
AUROC: 0.82, 95% CI: 0.79, 0.84) or full HIV RNA history (“HIV RNA/Electronic 
Adherence/Clinical” AUROC: 0.86, 95% CI: 0.84, 0.88) improved performance further 
(p<0.01 for each pairwise comparison). With failure defined as >400 copies/ml, 
corresponding AUROCs were slightly higher (Table 2). Figure 2 shows cross-validated 
sensitivity, specificity, positive and negative predicted value for each of the Super Learner 
models across a range of cutoffs.
Selective HIV RNA Testing
Figure 3 shows cross-validated estimated capacity savings for a range of sensitivities. With 
failure defined as >1000 copies/ml and cutoff chosen to maintain sensitivity >=95%, a 
testing rule based on non-virological clinical predictors alone achieved a capacity savings of 
15%. Capacity savings increased with addition of MEMS data to 22%, with further addition 
of a single baseline HIV RNA level to 31%, and with addition of full HIV RNA history to 
41%. Estimated cost savings per person-month MEMS follow-up increased from $9–$14 
with non-virological clinical data alone, to $18–$39 dollars after incorporating MEMS and 
HIV RNA data (Table 2). Capacity savings at 95% sensitivity were slightly lower with a 
failure threshold of 400 copies/ml (Table 2).
Discussion
We examined how well electronic adherence (MEMS) and clinical data, analyzed using 
Super Learner, could classify virological failure (HIV RNA >400 or >1000 copies/ml) in a 
heterogeneous population of HIV positive patients in the United States. MEMS-based 
measurement of percent doses taken resulted in poor classification of failure (AUROC 0.60–
0.64), as reported by others (AUROC<0.67).8 Super Learner applied to MEMS and non-
virological clinical data significantly improved AUROC (0.78–0.79). MEMS data also 
significantly improved classification of failure over non-virological clinical data alone, 
while addition of past HIV RNA data improved classification further.
While MEMS does not transmit data in real-time, it provides proof-of-concept that real-time 
electronic adherence monitoring, which is now available through other devices, could 
inform frequency and timing of HIV RNA testing.13,37,38 In order to investigate the 
potential for an electronic adherence-based algorithm to reserve HIV RNA testing for 
patients with non-negligible risk of failure, we evaluated the extent to which testing could 
have been reduced while detecting almost all failures without additional delay. Using a 
selective testing approach based on MEMS and clinical data, we estimated that 18–31% of 
HIV RNA tests could have been avoided (depending on failure definition and inclusion of a 
single baseline HIV RNA level) while missing no more than 5% of subjects failing on a 
given date. We were unable to evaluate the extent to which any missed failures would have 
been detected at a later date under a selective testing strategy because in our data failures 
that would have been missed were instead detected and responded to. Our analyses therefore 
censored data at date of first detected failure.
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Addition of past HIV RNA data improved capacity savings further to 34–41%. If a selective 
testing strategy were applied in practice, a reduced set of HIV RNA data would be available 
to guide real time decision-making (some HIV RNA tests would not have ben ordered). 
Therefore, capacity savings using an algorithm that incorporates full HIV RNA history 
should be seen as an upper bound.
Our results suggest an immediate gross cost savings of roughly $16–$29 per person-month 
of MEMS use, assuming access to a single baseline HIV RNA measurement. This estimate 
represents an upper limit for what the health care system might reasonably spend on all 
components of a real-time adherence monitoring system, which would need to include 
devices, monitoring staff, and data transmission, while remaining cost neutral. Our cost 
savings estimate was conservative, however, in that only HIV RNA tests with MEMS 
monitoring in the prior month could be deferred, and reported interruptions in monitoring 
were included in total MEMS time. We did not account for costs incurred by changes in 
second line regimen use, resistance testing, or disease progression, and we assumed that a 
reduction in HIV RNA testing would save both laboratory and associated clinic visit costs; 
excluding visit costs would reduce our estimated savings. Our estimates might also differ 
substantially under different HIV RNA monitoring schedules, in populations with different 
virological failure rates, and in settings where MEMS was used with fewer interruptions and 
over longer durations.
Furthermore, we conservatively assumed that real-time monitoring conferred no benefit, and 
evaluated a hypothetical system under which MEMS could be used to defer regularly 
scheduled tests, but not to trigger extra or early tests. In practice, real-time electronic 
adherence monitoring could be used to trigger tests between scheduled testing dates, which 
while increasing cost could introduce additional potentially significant benefits including 
opportunities to both detect failure earlier and to prevent it from occurring.39 While 
frequency of HIV RNA monitoring in our cohort was similar to that seen in standard clinical 
care, our results should thus be viewed as initial proof-of-concept for future investigation 
including full cost-effectiveness analysis.
More efficient strategies for HIV RNA testing are especially important in resource-limited 
settings where standard HIV RNA testing is cost prohibitive. A number of possible 
strategies for selective HIV RNA testing in resource-limited settings have been proposed. 
WHO-recommended CD4-based criteria have been repeatedly shown to have poor 
sensitivity for detecting failure,40–43 while a number of alternative clinical and CD4-based 
rules proposed for selective HIV RNA testing also exhibited moderate to poor sensitivity in 
validation data sets.4–6 However, a recent clinical prediction score that incorporated self-
report adherence, regular hemoglobin and CD4 monitoring, and new onset papular pruritic 
rash achieved more promising performance in Cambodia,22,44 as did pharmacy refill data, 
alone or in combination with CD4 counts, in South Africa.7 Robbins et. al. also achieved 
good classification of failure among US patients using adherence data abstracted from 
clinical notes, drug and alcohol use, and past appointment history in addition to HIV RNA, 
CD4 and ART data.45 While these studies were conducted using predictor variables not 
available in the current study, they provide additional proof-of-concept for a strategy of 
selective HIV RNA testing that incorporates adherence measures. The utility and cost-
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effectiveness of incorporating electronic adherence data in such a strategy remains to be 
determined. We found that a selective testing approach based on CD4 count and ART 
measures alone could achieve a 14–15% potential capacity savings while maintaining 
sensitivity at 95%. The performance of our classification rule might have been improved by 
including more extensive clinical history and self-reporting of non-adherence. Thus, while 
our study provides insight into classification performance achievable in settings where rich 
and carefully documented longitudinal clinical data are not available but electronic 
adherence data are, further investigation of the value added by electronic adherence data in 
settings with more extensive patient data remains of interest.
Our analyses focused on a machine-learning method (Super Learner) to build optimal 
predictors of virological failure, and evaluated the extent to which the resulting risk scores 
could be used to reduce HIV RNA testing while maintaining sensitivity at a fixed level if all 
patients with risk scores above a cutoff were tested. We focused on capacity savings rather 
than specificity as any initial false positives would be correctly classified with subsequent 
HIV RNA testing using this approach. Recently developed methods instead take the risk 
score and a constraint on testing as given and develop optimal tripartite rules, in which only 
patients with an intermediate risk score are tested.46 Combined application of these 
approaches is an exciting area of future research.
The patient population in this study included patients with varied clinical histories receiving 
care in a range of locations throughout the United States; value added by electronic 
adherence data may vary in different populations. Further, subjects were followed as part of 
different studies, with distinct protocols for data collection and quality control. We excluded 
any reported periods of MEMS nonuse from our adherence calculations; however, gaps in 
MEMS events might still reflect device malfunction or non-use rather than missed doses. 
Real time reporting of electronic adherence data may improve ability to distinguish between 
these possibilities through real time patient queries, and thus may improve classification 
performance achievable with MEMS data still further.13,38
In summary, our results support Super Learner as a promising approach to developing 
algorithms for selective HIV RNA testing based on the complex data generated by electronic 
adherence monitoring in combination with readily available clinical variables. A patient’s 
risk of current virological failure, based on time-updated clinical and MEMS data, could be 
made available to clinicians in real time (e.g., as an automated calculation in an electronic 
medical record or smart phone application) to help determine whether a clinic visit and/or 
HIV RNA test is indicated, allowing for personalized testing and visit schedules. Our results 
provide initial proof-of-concept for the potential of such an approach to reduce costs while 
maintaining outcomes.
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Figure 1. 
Cross-validated ROC Curves for classification of virological failure using four Super 
Learner prediction models and three-month “average adherence” (percent prescribed doses 
recorded by MEMS).
1a. Failure defined as HIV RNA level>1000 copies/ml
1b. Failure defined as HIV RNA level>400 copies/ml
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Figure 2. 
Cross validated performance measures for Super Learner-based classification of failure1
2a. Failure defined as HIV RNA level>1000 copies/ml
1Sens=Sensitivity; Spec= Specificity; NPV=negative predictive value; PPV=positive 
predictive value
2b. Failure defined as HIV RNA level>400 copies/ml
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Figure 3. 
Estimated capacity savings (proportion of HIV RNA tests avoided) achievable by a selective 
testing strategy with cutoff chosen to maintain a range of sensitivities.
3a. Failure defined as HIV RNA level>1000 copies/ml
3b. Failure defined as HIV RNA level>400 copies/ml
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Table 1
Sample Characteristics1
Baseline Variables2
Age (years)3 Median 41 (IQR: 36, 47)
Duration of known HIV status at time of enrollment (years)4 Median 9.2 (IQR: 4.0, 16.1)
HIV RNA level (copies/ml) Median 336.5 (IQR: 50, 2600)
CD4+ T cell count (cells/µl) Median 295 (IQR: 143, 444)
Male5 N=855 (64.7%)
Man who has sex with men6 N=499 (42.7%)
Injection drug use before HIV diagnosis7 N=186 (19.3%)
ART Naïve at time of enrollment8 N=217 (16.9%)
Time-varying Variables9
HIV RNA level>1000 copies/ml N=607 (19.6%)
Most recent CD4+ T cell count (cells/µl) Median 338 (IQR: 176, 500)
Time since most recent CD4+ T cell count (days) Median 142 (IQR: 79, 274)
Time since most recent HIV RNA (days) Median 45 (IQR: 28, 99)
Days monitored using MEMS in previous 3 months Median 78 (IQR: 28, 91)
Percent doses taken (%) in previous 3 months Median 84 (IQR: 50, 98)
Number of interruptions >= 24 hours in previous 3 months Median 4 (IQR: 1, 11)
Number of interruptions >= 72 hours in previous 3 months Median 0 (IQR: 0, 1)
NNRTI Regimen N=806 (26.0%)
Non-boosted PI Regimen N=553 (17.9%)
Boosted PI Regimen N=901 (29.1%)
Other10 N=836 (27%)
1
For analysis of failure=HIV RNA>1000 copies/ml; results for failure=HIV RNA>400 copies/ml differ slightly due to censoring at first failure.
2
Among 1478 patients meeting inclusion criteria
3
55 (10.5%) missing age
4
166 (11.2%) missing duration of known HIV status
5
157 (10.6%) missing sex
6
310 (21.0%) missing whether a man who has sex with men
7
510 (34.6%) missing injection drug use
8
192 (13.0%) missing whether ART naive at time of enrollment
9
Summarized over 3096 postbaseline HIV RNA tests meeting inclusion criteria.
10
Included regimens with two nucleoside reverse transcriptase inhibitors but no other reported drug, regimens based on fusion inhibitors, and 
unspecified/unknown regimens.
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